A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University

Phase 1HDT-401Positive

AI Analysis

Summary

HDT Bio Canada Inc. launched a Phase 1 clinical program in partnership with McGill University and The Neuro to evaluate HDT-401, an investigational locally administered RNA immune activator, for the treatment of glioblastoma in Canada.

Clinical Trial Data

Phase

Phase 1

Importance:5/10

Sentiment:

0.60

Phase 1glioblastomaRNA immune activatorCanadaclinical trial initiationpartnership

Related Companies

$BNN.DE

Read the original article

Published by PR Newswire Pharma on July 12, 2026 4:00 PM

Read Original